With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.
You may also be interested in...
J&J Highlights Late-Stage R&D Prospects Across Pharma Division
J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.
Janssen Builds A Pulmonary Pipeline: An Interview With Sue Dillon
Citing high unmet medical need and significant commercial opportunity, Janssen Research & Development has dived into pulmonary therapeutics. TA head of immunology Sue Dillon discusses the rationale, the indications and the therapeutic approaches the company is taking.
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.